GSK is acquiring 35Pharma for $950 million, and getting rights to HS235, a potential best-in-class PH treatment now in early clinical testing.

Acquisition includes HS235, a potentially best-in-class activin signalling inhibitor in clinical development for treatment of cardiopulmonary ...

Allison Dsouza was unable to walk a short distance without becoming winded. The Munhall resident’s trouble breathing led to a diagnosis of pulmonary hypertension, high blood pressure in the blood ...

Inhaled seralutinib demonstrated clinical activity in high-risk pulmonary arterial hypertension patients despite missing its primary phase 3 endpoint.

Scientists have used a novel gene therapy to halt the progression of pulmonary hypertension, a form of high blood pressure in the lung blood vessels that is linked to heart failure, according to a ...

Researchers estimate that about 1% of the global population has pulmonary hypertension — a disease caused by high blood pressure in the blood vessels that deliver oxygen to the lungs. Past studies ...

Blood vessels in the lungs aren't like the others in the body. This difference becomes clear in pulmonary hypertension, in which only the lungs' blood vessels stiffen progressively, leading to chronic ...

Please provide your email address to receive an email when new articles are posted on . Inhaled treprostinil is used to treat pulmonary hypertension with interstitial lung disease, and a study ...

Winrevair, also known as sotatercept-csrk, is a medicine used to treat pulmonary arterial hypertension (PAH), which causes high blood pressure in the arteries that go from your heart to your lungs.